Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Change in Receivables (2023)

Tango Therapeutics has reported Change in Receivables over the past 1 years, most recently at -$2.0 million for Q1 2023.

  • Quarterly results put Change in Receivables at -$2.0 million for Q1 2023, changed N/A from a year ago — trailing twelve months through Dec 2023 was -$2.0 million (changed N/A YoY), and the annual figure for FY2023 was -$2.0 million, changed.
  • Change in Receivables for Q1 2023 was -$2.0 million at Tango Therapeutics.
  • Over the last five years, Change in Receivables for TNGX hit a ceiling of -$2.0 million in Q1 2023 and a floor of -$2.0 million in Q1 2023.